Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells
| Autor: | Prachi R. Patel, Megan M. Davis, Joseph A. Fraietta, David M. Barrett, Simon F. Lacey, John Scholler, John Leferovich, Selene Nunez-Cruz, Stephan A. Grupp, Felipe Bedoya, J. Joseph Melenhorst, Michael C. Milone, Saba Ghassemi, Bruce L. Levine, Roddy S. O’Connor, Stefan Lundh, Changfeng Zhang, Carl H. June |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cytotoxicity Immunologic Cancer Research Adoptive cell transfer Time Factors medicine.medical_treatment T-Lymphocytes Immunology Antigens CD19 Cell Culture Techniques Lymphocyte Activation Immunotherapy Adoptive CD19 Article 03 medical and health sciences Mice 0302 clinical medicine Antigen Antigens Neoplasm Cell Line Tumor medicine Animals Humans Receptors Chimeric Antigen biology business.industry Cell Differentiation Immunotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Xenograft Model Antitumor Assays In vitro Chimeric antigen receptor Leukemia 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Cancer research business Ex vivo |
| Zdroj: | Cancer Immunol Res |
| Popis: | The success of chimeric antigen receptor (CAR)–mediated immunotherapy in acute lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed cytotoxicity against specific tumor antigens. The efficacy of CAR T-cell therapy depends on the engraftment and persistence of T cells following adoptive transfer. Most protocols for T-cell engineering routinely expand T cells ex vivo for 9 to 14 days. Because the potential for engraftment and persistence is related to the state of T-cell differentiation, we hypothesized that reducing the duration of ex vivo culture would limit differentiation and enhance the efficacy of CAR T-cell therapy. We demonstrated that T cells with a CAR-targeting CD19 (CART19) exhibited less differentiation and enhanced effector function in vitro when harvested from cultures at earlier (day 3 or 5) compared with later (day 9) timepoints. We then compared the therapeutic potential of early versus late harvested CART19 in a murine xenograft model of ALL and showed that the antileukemic activity inversely correlated with ex vivo culture time: day 3 harvested cells showed robust tumor control despite using a 6-fold lower dose of CART19, whereas day 9 cells failed to control leukemia at limited cell doses. We also demonstrated the feasibility of an abbreviated culture in a large-scale current good manufacturing practice–compliant process. Limiting the interval between T-cell isolation and CAR treatment is critical for patients with rapidly progressing disease. Generating CAR T cells in less time also improves potency, which is central to the effectiveness of these therapies. Cancer Immunol Res; 6(9); 1100–9. ©2018 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|